Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | DTYMK | P23919 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | CCNK | O75909 | 1/20 | 0.35 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25426035 | 0.96 | CYP11B2 (0.39) | CYP11B2HSD11B1MAP2K1POLBKIT | |
| SCHEMBL30509709 | 0.96 | CYP11B2 (0.39) | CYP11B2HSD11B1MAP2K1POLBKIT | |
| SCHEMBL30509700 | 0.86 | HSD11B1 (0.42) | CYP11B2HSD11B1MAP2K1POLBDTYMK | |
| SCHEMBL25429671 | 0.86 | HSD11B1 (0.42) | CYP11B2HSD11B1MAP2K1POLBDTYMK | |
| SCHEMBL25427796 | 0.79 | HSD11B1 (0.41) | HSD11B1MAP2K1POLBDTYMKJAK3 | |
| SCHEMBL30509712 | 0.79 | HSD11B1 (0.41) | HSD11B1MAP2K1POLBDTYMKJAK3 | |
| SCHEMBL30509683 | 0.78 | HSD11B1 (0.42) | HSD11B1MAP2K1POLBDTYMKJAK3 | |
| SCHEMBL25428242 | 0.78 | HSD11B1 (0.42) | HSD11B1MAP2K1POLBDTYMKJAK3 | |
| SCHEMBL25866544 | 0.78 | MAP2K1 (0.39) | HSD11B1MAP2K1POLBDTYMKJAK3 | |
| SCHEMBL1815353 | 0.74 | HSD11B1 (0.61) | HSD11B1MAP2K1POLBDTYMKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4466266-B1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | TRANSNEURAL THERAPEUTICS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12486268-B2 | Fused heterocycles as 5-HT2A receptor agonists | Transneural Therapeutics, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12459944-B2 | Fused heterocycles as 5-HT2A receptor agonists | Transneural Therapeutics, Inc. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250243199-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | Transneural Therapeutics, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-20240425503-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | Transneural Therapeutics, Inc. | 2024-12-26 | — | — | US | disclosed |
| EP-4466266-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | Transneural Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023141225-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | ONSERO THERAPEUTICS INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141225-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | ONSERO THERAPEUTICS INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459944-B2 | Fused heterocycles as 5-HT2A receptor agonists | HTR2A, HTR2C, HTR5A | CYP11B2 486/4885HSD11B1 2233/4885MAP2K1 2999/4885 |
| US-20250243199-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR5A | CYP11B2 486/4885HSD11B1 2233/4885MAP2K1 2999/4885 |
| US-20240425503-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR1A | CYP11B2 616/4885HSD11B1 2614/4885MAP2K1 3311/4885 |
| US-12486268-B2 | Fused heterocycles as 5-HT2A receptor agonists | HTR2A, HTR2C, HTR5A | CYP11B2 486/4885HSD11B1 2233/4885MAP2K1 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.